NCT00385385View on ClinicalTrials.gov

RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease

PHASE2UnknownINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

October 31, 2006

Study Completion Date

September 30, 2008

Conditions
Coronary Artery DiseaseCerebrovascular DiseasePeripheral Vascular Disease
Interventions
DRUG

Rifalazil

Trial Locations (6)

11576

RECRUITING

St. Francis Hospital, Roslyn

11794

RECRUITING

Stony Brook University Medical Center, Stony Brook

48910

RECRUITING

Thoracic & Cardiovascular Healthcare Foundation, Lansing

77030

RECRUITING

Baylor College of Medicine, Houston

98122

RECRUITING

Swedish Medical Center, Seattle

Unknown

RECRUITING

Robarts Research Institute, London

Sponsors

Lead Sponsor

ActivBiotics
All Listed Sponsors
lead

ActivBiotics

INDUSTRY

NCT00385385 - RESTORE-IT-Study of Rifalazil in Chlamydia Pneumoniae Seropositive Patients With a History of Atherosclerotic Disease | Biotech Hunter | Biotech Hunter